Medical Marijuana Companies Sue DEA In Federal Court Over Restrictions It Imposed For Rescheduling Protections


Three marijuana companies are taking the Drug Enforcement Administration (DEA) to court over restrictions the agency is placing on cannabis businesses under the Trump administration’s federal rescheduling move.

Last month, DEA announced it had granted federal registration and protections to hundreds of medical marijuana businesses in line with rescheduling while also issuing new guidance warning that cannabis companies have until November 29 to begin sourcing product only from and to other operators that have also been granted or applied for registration in a timely fashion.

Lawyers for Standard Wellness Utah, Verde Americano in Arizona and NW Confections OK in Oklahoma said in a petition for review filed on Wednesday before the U.S. Court of Appeals for the District of Columbia Circuit that the federal agency’s move is already causing “supply-chain disruptions” in state medical cannabis markets.

“This perfunctorily issued deadline ignores the realities of state markets, which prohibit interstate commerce—meaning that operators are entirely dependent on intrastate markets for manufacture, distribution, and dispensing,” the filing says. “By prohibiting ‘timely’ applicants from transacting with ‘non-timely’ applicants, the deadline overlooks that a given state may not have enough timely operators to satisfy its needs.”

“By bifurcating state medical marijuana marketplaces as of a date certain, DEA has disrupted settled expectations: after November 29, Standard Wellness Utah will lose monthly sales averaging ~$275,900 and the suppliers of about 16% of its oil; NW Confections expects its Oklahoma business to become insolvent; and Verde expects to reduce its workforce by 70%.”

Arguing that “DEA has acted unlawfully and without authority,” the marijuana companies are asking the court to issue a ruling or an administrative stay on the agency’s actions prior to November 25.

The petition says that the companies directly asked DEA to suspend this month’s upcoming deadline but that it has not replied.

In the meantime, the “market reacted immediately” to the agency’s recent letter to timely applicants that laid out the restrictions.

“Utah pharmacies and processors refuse to deal with non-timely applicants; one is quarantining about $80,000 of Standard Wellness Utah product delivered the day before it refused further purchases. Two major Verde customers demanded proof of its DEA status, and a large multi-location customer paused its orders. NW Confections has identified 15 non-timely dispensary customers, operating about 23 locations, that it will stop serving after November 29.”

The October 30 directive to cannabis businesses—titled “DEA Medical Marijuana Timely Applicant Information”—was unlawful for three reasons, the new petition argues.

First, it claims that the DEA move contravenes the marijuana rescheduling order that Attorney General Todd Blanche issued in April while also exceeding the agency’s authority.

“The Final Order promised that ‘early applicants may lawfully operate under their state-issued licenses during the pendency of review.’ The regulation likewise authorizes timely applicants to operate ‘in conformity with a state-issued license during the pendency of the application.’ Neither sets a calendar end date, and neither conditions that authority on the status of an applicant’s trading partners; it lasts as long as the application is pending. Yet the Information requires timely applicants to ‘verify the status of their existing trading partners’ and make ‘necessary adjustments to their supply chain’ by November 29, 2026.”

The lawsuit also argues that the DEA move amounts to a legislative rule that was improperly issued without notice and comment.

“The requirement that timely applicants verify their trading partners’ status and restructure their supply chains, on pain of denial or revocation, exists nowhere but in the Information.”

Finally, the petition says the agency’s move is arbitrary and capricious, because “DEA failed to consider the reliance interests it discarded.”

“DEA recognized that timely applicants would need to ‘make necessary adjustments to their supply chain,’ then gave them 30 days… The Information never asks what severing existing trading relationships on 30 days’ notice would cost, who would bear it, or whether it is justified. Those costs fall on both sides of every severed relationship: on timely applicants that lose their trading partners, and on non-timely licensees…that lose their customers and suppliers.”

The companies are asking the court to place a stay on the DEA directive, saying that “on November 29, the Information will sever the supply relationships on which each Petitioner depends, and nothing this Court does later can restore the customers, suppliers, shelf space, employees, and licenses lost.”

Meanwhile, DEA has been refusing to grant federal registration and protections to medical marijuana businesses in at least six states and Washington, D.C.

In orders to show cause sent to applicants in California, Delaware, the District of Columbia, Illinois, Minnesota, North Dakota and Oregon, the agency has cited various provisions of those states’ laws as reasons it cannot register any business within those jurisdictions.

Although the documents differ from state to state, there are similarities, according to industry sources who have reviewed the orders, the text of some of which have been shared with Marijuana Moment.

For example, the DEA orders generally cite some of the states’ allowance of businesses to sell non-medical marijuana as a violation of the Controlled Substances Act’s (CSA) “closed system” for medical access to scheduled drugs and of the U.S.’s international treaty obligations.

Some of the documents also single out state laws that allow certain patients to access medical cannabis without a doctor’s written recommendation.

State cannabis regulators have expressed frustrations with the agency’s actions and general refusal to communicate with them about its plans.

The Cannabis Regulators Association’s Gillian Schauer—who represents state officials across the U.S.—argued in a recent Marijuana Moment op-ed that the way DEA is implementing rescheduling has “created deep uncertainty and disruption for regulators, patients and market operators” and came with “little or no advance notice to state regulators and minimal communication afterward.”

“Supply chains in many states will not have enough cultivators, manufacturers and dispensaries to support a viable supply chain in either the DEA market or the state-only market,” she wrote. “With bifurcated and incomplete supply chains in states, some businesses will not survive in either market, patient access will be impacted, diversion and inversion will become more difficult for regulators to detect, health and safety compliance will be eroded and state revenues that support a variety of public services will decrease.”

Read the new lawsuit against the DEA below:

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Become a patron at Patreon!



Source link

Back To Top